Indicators
Indicators
Value
Direction
MACD(12,26,9)
-25.770
Neutral
RSI(14)
57.774
Neutral
STOCH(KDJ)(9,3,3)
37.625
Buy
ATR(14)
29.122
High Vlolatility
CCI(14)
-38.208
Neutral
Williams %R
62.638
Sell
TRIX(12,20)
0.324
Sell
StochRSI(14)
100.000
Buy
Eli Lilly and Co
LLY1027.510USD
+18.520+1.83%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
971.86BMarket Cap
50.13P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Eli Lilly and Co
Currency: USD Updated: 2025-12-12Key Insights
Eli Lilly and Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1053.87.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eli Lilly and Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
33
analysts
Buy
Current Rating
1053.869
Target Price
+5.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Eli Lilly and Co Highlights
StrengthsRisks
Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.
As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."
Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.
The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.
By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.
Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 57.82% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 45.04B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 45.87%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 45.87%.
Undervalued
The company’s latest PE is 50.13, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 789.85M shares, decreasing 0.81% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 25.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.87.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Eli Lilly and Co is 8.94, ranking 24/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.60B, representing a year-over-year increase of 53.87%, while its net profit experienced a year-over-year increase of 475.34%.
Score
Financials
6.01
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.01
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.66
Eli Lilly and Co's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Eli Lilly and Co is 5.27, ranking 150/159 in the Pharmaceuticals industry. Its current P/E ratio is 50.13, which is 171.46% below the recent high of 136.10 and 18.69% above the recent low of 40.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 46/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Eli Lilly and Co is 8.00, ranking 56/159 in the Pharmaceuticals industry. The average price target for Eli Lilly and Co is 1055.00, with a high of 1500.00 and a low of 706.04.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
33
analysts
Buy
Current Rating
1053.869
Target Price
+5.64%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
33
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
Gilead Sciences Inc
GILD
31
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Eli Lilly and Co is 7.30, ranking 74/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1100.63 and the support level at 965.76, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1002.068
Buy
MA10
1017.271
Buy
MA20
1038.112
Sell
MA50
934.553
Buy
MA100
835.105
Buy
MA200
814.602
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Eli Lilly and Co is 7.00, ranking 44/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 83.53%, representing a quarter-over-quarter decrease of 0.89%. The largest institutional shareholder is The Vanguard, holding a total of 80.59M shares, representing 8.52% of shares outstanding, with 2.43% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Lilly Endowment, Inc.
PNC Investments LLC
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Capital Research Global Investors
Fidelity Management & Research Company LLC
Geode Capital Management, L.L.C.
Capital World Investors
Wellington Management Company, LLP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Eli Lilly and Co is 8.97, ranking 21/159 in the Pharmaceuticals industry. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.35
VaR
+2.70%
240-Day Maximum Drawdown
+32.71%
240-Day Volatility
+38.83%
Return
Best Daily Return
60 days
+8.18%
120 days
+8.18%
5 years
+14.87%
Worst Daily Return
60 days
-3.67%
120 days
-14.14%
5 years
-14.14%
Sharpe Ratio
60 days
+3.96
120 days
+1.78
5 years
+1.27
Risk Assessment
Maximum Drawdown
240 days
+32.71%
3 years
+34.83%
5 years
+34.83%
Return-to-Drawdown Ratio
240 days
+0.95
3 years
+1.90
5 years
+2.28
Skewness
240 days
-0.50
3 years
+0.24
5 years
+0.38
Volatility
Realised Volatility
240 days
+38.83%
5 years
+34.23%
Standardised True Range
240 days
+2.45%
5 years
+1.41%
Downside Risk-Adjusted Return
120 days
+196.89%
240 days
+196.89%
Maximum Daily Upside Volatility
60 days
+29.80%
Maximum Daily Downside Volatility
60 days
+17.62%
Liquidity
Average Turnover Rate
60 days
+0.47%
120 days
+0.45%
5 years
--
Turnover Deviation
20 days
+86.75%
60 days
+25.56%
120 days
+21.57%
Peer Comparison
Pharmaceuticals
Eli Lilly and Co
LLY
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Eli Lilly and Co?
The TradingKey Stock Score provides a comprehensive assessment of Eli Lilly and Co based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Eli Lilly and Co’s performance and outlook.
How do we generate the financial health score of Eli Lilly and Co?
To generate the financial health score of Eli Lilly and Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Eli Lilly and Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Eli Lilly and Co.
How do we generate the company valuation score of Eli Lilly and Co?
To generate the company valuation score of Eli Lilly and Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Eli Lilly and Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Eli Lilly and Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Eli Lilly and Co.
How do we generate the earnings forecast score of Eli Lilly and Co?
To calculate the earnings forecast score of Eli Lilly and Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Eli Lilly and Co’s future.
How do we generate the price momentum score of Eli Lilly and Co?
When generating the price momentum score for Eli Lilly and Co, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Eli Lilly and Co’s prices. A higher score indicates a more stable short-term price trend for Eli Lilly and Co.
How do we generate the institutional confidence score of Eli Lilly and Co?
To generate the institutional confidence score of Eli Lilly and Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Eli Lilly and Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Eli Lilly and Co.
How do we generate the risk management score of Eli Lilly and Co?
To assess the risk management score of Eli Lilly and Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Eli Lilly and Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Eli Lilly and Co.
